Allurion Technologies (ALURD) Net Income towards Common Stockholders Growth (1y) (2023 - 2026)
Allurion Technologies (ALURD) Net Income towards Common Stockholders Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 186.78 Bn | 179.48 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 131.95 Bn | 129.07 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 111.27 Bn | 102.05 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 68.58 Bn | 67.13 Bn | 3.61 Bn | 98.96% |
| 5 | Edwards Lifesciences | 48.31 Bn | 44.63 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 29.23 Bn | 26.94 Bn | 1.98 Bn | -30.10% |
| 7 | Dexcom | 28.90 Bn | 27.78 Bn | 750.30 Mn | 89.28% |
| 8 | Smith & Nephew | 28.19 Bn | 27.62 Bn | - | - |
| 9 | Koninklijke Philips | 24.33 Bn | 21.29 Bn | 2.01 Bn | 98.68% |
| 10 | Allurion Technologies | 60.75 Mn | 55.69 Mn | 1.23 Mn | -182.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -182.60% |
| Dec 31, 2025 | 34.63% |
| Sep 30, 2025 | -236.03% |
| Jun 30, 2025 | -12.17% |
| Mar 31, 2025 | 269.69% |
| Dec 31, 2024 | 55.08% |
| Sep 30, 2024 | 139.92% |
| Jun 30, 2024 | 63.37% |
| Mar 31, 2024 | 110.78% |
| Dec 31, 2023 | -63.53% |
| Sep 30, 2023 | -52.99% |
| Jun 30, 2023 | -270.65% |